6th iPSC Drug Development Summit
September 9 - 10, 2026 - MA USHanson Wade
info@hansonwade.com
Phone:+1 617 455 4188
As induced pluripotent stem cell (iPSC) therapies move from promise to proof, the 6th iPSC Drug Development Summit returns at a critical moment for the field. With landmark regulatory progress, late-stage clinical programs advancing, and unprecedented investment flowing into iPSC platforms, the focus has shifted decisively toward scalability, manufacturability, and commercial readiness. This is the only industry summit dedicated exclusively to advancing iPSC-derived therapies from early research through clinical translation and GMP-ready manufacturing. Bringing together biopharma innovators, academic leaders, regulators, and investors, the meeting provides an end-to-end view of the development challenges teams are navigating today and the solutions being applied in practice. Across two focused tracks covering preclinical development and process development and CMC, attendees will gain real-world insights into genome editing strategies, donor and cell line selection, functional QC, scale-up, cryopreservation, regulatory alignment, and investment readiness. The agenda features 25+ expert speakers from leading organizations including Astellas Pharma, BlueRock Therapeutics, Aspen Neuroscience, Vertex Pharmaceuticals, and more, sharing new clinical data and hard-won development lessons across indications such as Parkinson's disease, ocular disorders, diabetes, and oncology. Designed for scientists, engineers, and decision-makers actively building iPSC pipelines, this summit offers unparalleled opportunities to pressure‑test strategies, benchmark against leaders, and connect with the ecosystem shaping the future of iPSC therapeutics. Free to attend for qualified biopharma professionals and academics working on iPSC therapies. Time: 7:30 AM - 4:30 PM